Internal Med Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years
Osteoporosis International, 10/13/09

Bruyère O et al. – Short-term changes in biochemical markers of bone formation are associated with future BMD changes in patients treated with strontium ranelate, suggesting a bone-forming activity of this treatment, but are not appropriate to monitor the efficacy of strontium ranelate at the individual level.

Methods

From the SOTI and TROPOS trials, bone-specific alkaline phosphatase (BALP), C-terminal propeptide of type I procollagen (PICP), serum C-terminal telopeptides (S-CTX) and urine N-terminal telopeptides of type I collagen (U-NTX) assessed at baseline and after 3 months
2373 women included

Results

Multiple regression analysis showed 3-month changes in PICP and BALP but not s-CTX I nor s-NTX I significantly associated with 3-year BMD changes at lumbar spine and femoral neck
Changes in s-CTX I, PICP and BALP significantly associated with change in total proximal femur BMD
Changes in biochemical markers explain < 8% of BMD changes
3-month changes in BALP, PICP s-CTX I and s-NTX I not significantly associated with fracture incidence